8 recruiting, 3 completed, 2 active not recruiting, 2 withdrawn. 7 Phase 2, 5 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow this condition Literature Review of Stage III Hypopharyngeal Carcinoma AJCC v8 trials Research Report on Stage III Hypopharyngeal Carcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-20 |
| A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation Best Practice, Consensus Auditory-Perceptual Evaluation of Voice, Diagnostic Imaging - Clinical Stage II HPV-Mediated (p16-pos) Oropharyngeal Carcinoma, Clinical Stage III HPV-Mediated (p16-pos) Oropharyngeal Carcinoma | Not applicable | Withdrawn | Mayo Clinic | 2022-12-01 | 2023-01-06 | |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 46 | 2022-09-19 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
| Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration - Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2020-10-19 | 2024-10-29 |
| Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy - Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Completed | Hyunseok Kang, MD | 16 | 2020-10-14 | 2024-06-28 |
| Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Celecoxib, Placebo, Quality-of-Life Assessment - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Terminated | University of Utah | 13 | 2019-11-27 | 2025-02-12 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer Biospecimen Collection, Questionnaire Administration - Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Recruiting | M.D. Anderson Cancer Center | 471 | 2016-12-29 | 2026-10-06 | |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 189 | 2016-11-23 | 2026-09-14 |
Carcinoma (16) · Hypopharyngeal Neoplasms (16) · Laryngeal Neoplasms (16) · Mouth Neoplasms (13) · Oropharyngeal Neoplasms (13) · Squamous Cell Carcinoma of Head and Neck (9) · Nasopharyngeal Carcinoma (3) · Lymphoid Interstitial Pneumonia (1) · Melanoma (1) · Neoplasms, Unknown Primary (1) · Paranasal Sinus Neoplasms (1) · Salivary Gland Neoplasms (1) · Stomatitis (1)
Head and Neck Neoplasms (16) · Laryngeal Diseases (16) · Neoplasms (16) · Neoplasms by Histologic Type (16) · Neoplasms by Site (16) · Neoplasms, Glandular and Epithelial (16) · Otorhinolaryngologic Diseases (16) · Otorhinolaryngologic Neoplasms (16) · Pharyngeal Diseases (16) · Pharyngeal Neoplasms (16) · Respiratory Tract Diseases (16) · Respiratory Tract Neoplasms (16) · Stomatognathic Diseases (16) · Mouth Diseases (13) · Carcinoma, Squamous Cell (9)
Magnetic Resonance Spectroscopy (8) · Radiotherapy, Intensity-Modulated (7) · Specimen Handling (7) · 1,2-diaminocyclohexaneplatinum II citrate (5) · Cisplatin (5) · Platinum (4) · (225)Ac-DOTA-c(RGDyK) (2) · Biopsy (2) · Carboplatin (2) · Cetuximab (2) · Practice Guidelines as Topic (2) · Radiation (2) · Radiosurgery (2) · Radiotherapy (2) · Radiotherapy, Image-Guided (2)
National Cancer Institute (NCI) (6) · ECOG-ACRIN Cancer Research Group (2) · M.D. Anderson Cancer Center (2) · NRG Oncology (2) · Emory University (1) · Hyunseok Kang, MD (1) · Mayo Clinic (1) · University of Utah (1)
United States (14) · Canada (2)
Loren K Mell (2) · Yvonne M Mowery (2) · Amol M Takalkar, MD, MS, MBA, FACNM (1) · Clifton D Fuller (1) · David M Brizel (1) · Eileen H Shinn (1) · Heath D Skinner (1) · Hyunseok Kang, MD (1) · Lisa Crujido (1) · Malcolm D Mattes (1) · Maura L Gillison (1) · Richard Cannon, MD (1) · Robert Ferris (1) · Siwen Hu-Lieskovan (1)
PMID 34841093, PMID 38416544, PMID 39551064
U10CA180868 (3), U10CA180820 (2), UM1CA186690 (2), P30CA042014 (1), P30CA138292 (1), R21DE019954 (1), U10CA180888 (1), UG1CA189867 (1), UM1CA186644 (1)